Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$4.52 - $10.57 $948,549 - $2.22 Million
209,856 New
209,856 $2.22 Million
Q3 2020

Nov 13, 2020

SELL
$10.34 - $15.2 $719,291 - $1.06 Million
-69,564 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$7.81 - $17.0 $567,466 - $1.24 Million
-72,659 Reduced 51.09%
69,564 $982,000
Q1 2020

May 13, 2020

BUY
$5.42 - $17.75 $770,848 - $2.52 Million
142,223 New
142,223 $1.31 Million
Q4 2019

Feb 10, 2020

SELL
$5.84 - $14.9 $106,632 - $272,059
-18,259 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$6.83 - $13.0 $392,943 - $747,916
-57,532 Reduced 75.91%
18,259 $125,000
Q2 2019

Aug 14, 2019

BUY
$2.3 - $13.79 $174,319 - $1.05 Million
75,791 New
75,791 $917,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Eam Global Investors LLC Portfolio

Follow Eam Global Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Global Investors LLC with notifications on news.